On November 26, 2020 Golden Biotechnology Corp.(GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, reported that its new drug Antroquinonol (HOCENA) outperforms the other listing drugs for the treatment of relapsed AML (acute myeloid leukemia) patients in its Phase 2 clinical study conducted in Russia (Press release, Golden Biotechnology, NOV 26, 2020, View Source;outperforms-listing-drugs-in-relapsed-acute-myeloid-leukemia-301181008.html [SID1234571803]). The outcome measures demonstrated higher remission rates (50%, CR/Cri) and survival rates guaranteeing fewer patients will require blood transfusions. This has made high safety possible during breakthroughs for AML treatment with remarkable monotherapy without combined chemotherapy. The new drug Antroquinonol has been granted orphan drug designation (ODD) by the U.S. FDA for the treatment of AML in 2015. GoldenBiotech has achieved excellent breakthrough in the unmet medical needs in AML therapy which many global pharmaceutical companies are targeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Breakthrough in AML Treatment! GoldenBiotech’s new drug clinical trial of Antroquinonol.
Clinical Results Summary:
*Primary Outcome Measure- overall remission rate (CR/CRi): 50%
*Secondary Outcome Measures
80% of patients showed that their blasts count were less than 5%
90% of patients did not need blood transfusion during trial period
100% of patients were all alive during trial period (6 months)
No serious side effect
The primary efficacy indicator results exhibit that the overall remission rate (CR/CRi) of patients with relapsed acute myeloid leukemia reaches 50%. This is higher than those of other listing drugs in their Phase 2 trial ranging approximately from 21%~33% in (CR/CRi). 80% of patients’ abnormal blasts counts in bone marrow or blood were decreased to be less than 5% after treatment. For the secondary outcome measures results the overall survival rate of patients with relapsed AML reached 100% by the 6th month after treatment. This amplifies the possibility of patients receiving bone marrow transplantation. Furthermore, 90% of patients do not need to undergo blood transfusion during treatment with Antroquinonol (Hocena). Oral treatments and the decrease in blood transfusions have greatly improved the quality of life of AML patients. There is no significant side effect (SAE) that has occurred during the 6-month treatment period. The dose trial is administered orally at home by taking 200 mg twice a day.
The trial of Antroquinonol (HOCENA), Protocol No. GHAML-2-001, was an open-label, non-randomized, Phase 2a study to evaluate efficacy and safety/tolerability profiles in adult patients with relapsed acute myeloid leukemia (AML) or at initial diagnosis when no intensive treatment is possible.
There is no standard treatment for relapsed/refractory adult acute myeloid leukemia (AML) patients. Based on the confidence achieved in the trial results for the treatment of second-line and recurrent AML patients, GoldenBiotech will apply the clinical trial (IND) to the U.S. FDA for the Phase 2 clinical trials as the first-line treatment of AML and continue to expand the spectrum of indications of Antroquinonol in other leukemia treatment fields including multiple myeloma (MM), chronic myelogenous leukemia (CML), and pediatric leukemia.
The majority of AML patients need to undergo blood transfusions and chemotherapy to kill cancer cells due to abnormal differentiation of blood cells and proliferation of myeloblasts. Current therapies are combined with chemotherapy often causing serious side effects resulting in poor prognosis of treatment for relapsed AML patients. AML ranks the second highest incidence in all leukemia but it has the highest mortality rate and the lowest five-year survival rate (about only 25%).
It is estimated that there will be about 62,000 patients with acute myeloid leukemia (AML) in 2020. According to the reports from GlobalData and other institutions, the global AML therapeutic drug market is expected to increase from USD 1.4 billion in 2019 to 5.1 billion in 2029 with a compound annual growth rate (CAGR) of 13.6%.
About Antroquinonol
Antroquinonol was discovered in 2006 by Golden Biotechnology Corp..Its compound structure, preparation methods and applicable indications have been protected with patents worldwide. The recent approved by FDA and undergoing clinical trial of new drug Antroquinonol is a Phase 2 clinical trial for mild to moderate COVID-19 hospitalized patients in the USA. This is the first Taiwanese new drug approved by FDA for the Phase 2 clinical trial in Covid-19. Antroquinonol has shown anti-viral, anti-inflammatory and anti-fibrotic characteristics in past animal studies, suggesting high likelihood in becoming successful treatment option for coronavirus-induced pneumonia.
Learn more about the trial and contact information: Antroquinonol – Covid-19 Clinical Trial.
Other pipelines include non-small cell lung cancer (NSCLC), pancreatic cancer, acute myeloid leukemia, hypercholesterolemia and hyperlipidemia, atopic dermatitis and hepatitis. Research on neurogenic disorders like Alzheimer’s disease (AD) treatment and prevention are also in good process. Antroquinonol has received ODD (Orphan drug designation) approval by US FDA for treatment of Acute Myeloid Leukemia(AML), Hepatocelluar carcinoma (Liver cancer, HCC) and Pancreatic Cancer in 2015. For ODD in Pancreatic cancer has also received approval by European EMA in 2017.